Any feedback?
Please rate this page
(literature.php)
(0/150)

BRENDA support

Literature summary for 2.7.7.48 extracted from

  • Morse, J.; Lalonde, T.; Xu, S.; Liu, W.
    Learning from the Past Possible urgent prevention and treatment options for severe acute respiratory infections caused by 2019-nCoV (2020), ChemBioChem, 21, 730-738 .
    View publication on PubMed

Inhibitors

Inhibitors Comment Organism Structure
aurintricarboxylic acid
-
Severe acute respiratory syndrome-related coronavirus
additional information the high sequence conservation between SARS-CoV RNA-dependent RNA polymerase (RdRp) and SARS-CoV-2 RNA polymerase makes it very likely that any potent agents developed for the SARS-CoV RdRp will exhibit equal potency and efficacy on the SARS-CoV-2 enzyme Severe acute respiratory syndrome coronavirus 2
additional information the high sequence conservation between SARS-CoV RNA-dependent RNA polymerase (RdRp) and SARS-CoV-2 RNA polymerase makes it very likely that any potent agents developed for the SARS-CoV RdRp will exhibit equal potency and efficacy on the SARS-CoV-2 enzyme Severe acute respiratory syndrome-related coronavirus
remdesivir
-
Severe acute respiratory syndrome-related coronavirus
ribavirin
-
Severe acute respiratory syndrome-related coronavirus

Organism

Organism UniProt Comment Textmining
Severe acute respiratory syndrome coronavirus 2 MN908947 i.e. SARS-CoV-2
-
Severe acute respiratory syndrome-related coronavirus P0C6X7 human, i.e. SARS-CoV
-

Synonyms

Synonyms Comment Organism
RDRP
-
Severe acute respiratory syndrome-related coronavirus
RDRP
-
Severe acute respiratory syndrome coronavirus 2
RNA-dependent RNA polymerase
-
Severe acute respiratory syndrome coronavirus 2

General Information

General Information Comment Organism
drug target the high sequence conservation between SARS-CoV RNA-dependent RNA polymerase (RdRp) and SARS-CoV-2 RNA polymerase makes it very likely that any potent agents developed for the SARS-CoV RdRp will exhibit equal potency and efficacy on the SARS-CoV-2 enzyme Severe acute respiratory syndrome-related coronavirus
drug target the high sequence conservation between SARS-CoV RNA-dependent RNA polymerase (RdRp) and SARS-CoV-2 RNA polymerase makes it very likely that any potent agents developed for the SARS-CoV RdRp will exhibit equal potency and efficacy on the SARS-CoV-2 enzyme Severe acute respiratory syndrome coronavirus 2